Impact of hormone therapy on false-positive recall and costs among women undergoing screening mammography

Medical Care

Volumn 44, Issue 1, 2006, Pages 62-69

  Boudreau, Denise M ^a   Buist, Diana S M ^a   Rutter, Carolyn M ^a   Fishman, Paul A ^a   Beverly, Kevin R ^a   Taplin, Stephen ^a  

^a CENTER FOR HEALTH STUDIES   (United States)

Author keywords

Breast cancer; Costs; False positive; Hormone therapy; Mammography; Recall

Indexed keywords

ADULT; AGED; ARTICLE; BREAST TUMOR; COHORT ANALYSIS; COST; ESTROGEN THERAPY; FEMALE; HUMAN; LABORATORY DIAGNOSIS; MAMMOGRAPHY; MIDDLE AGED; RADIOGRAPHY; RECALL; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; COHORT STUDIES; COSTS AND COST ANALYSIS; ESTROGEN REPLACEMENT THERAPY; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; MAMMOGRAPHY; MENTAL RECALL; MIDDLE AGED; WASHINGTON;

EID: 33644790171     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mlr.0000188969.83608.92     Document Type: Article

References (43)

1. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA. 2003;289:3243-3253.
2. Turgeon JL, McDonnell DP, Martin KA, et al. Hormone therapy: physiological complexity belies therapeutic simplicity. Science. 2004; 304:1269-1273.
3. Warren MP. A comparative review of the risks and benefits of hormone replacement therapy regimens. Am J Obstet Gynecol. 2004;190:1141-1167.
4. Buist DSM, Newton KM, Miglioretti DL, et al. Hormone therapy prescribing patterns in the United States. Obstet Gynecol. 2004;104:1042-1050.
5. Laya MB, Larson EB, Taplin SH, et al. Effect of estrogen replacement therapy on the specificity and sensitivity of screening mammography. J Natl Cancer Inst. 1996;88:643-649.
6. Litherland JC, Stallard S, Hole D, et al. The effect of hormone replacement therapy on the sensitivity of screening mammograms. Clin Radiol. 1999;54:285-288.
7. Litherland JC. The effects of HRT on screening mammography. Breast. 2000;9:117-124.
8. Seradour B, Esteve J, Heid P, et al. Hormone replacement therapy and screening mammography: analysis of the results in the Bouches du Rhone programme. J Med Screen. 1999;6:99-102.
9. Kavanagh AM, Mitchell H, Giles GG. Hormone replacement therapy and accuracy of mammographic screening. Lancet. 2000;355:270-274.
10. Tabar L, Dean PB, Kaufman CS, et al. A new era in the diagnosis of breast cancer. Surg Oncol Clin N Am. 2000;9:233-277.
11. Kerlikowske K, Grady D, Rubin SM, et al. Efficacy of screening mammography. A meta-analysis. JAMA. 1995;273:149-154.
12. Quinn MJ. Cancer trends in the United States - a view from Europe. J Natl Cancer Inst. 2003;95:1258-1261.
13. Rutter CM, Mandelson MT, Laya MB, et al. Changes in breast density associated with initiation, discontinuation, and continuing use of hormone replacement therapy. JAMA. 2001;285:171-176.
14. Stomper PC, Van Voorhis BJ, Ravnikar VA, et al. Mammographic changes associated with postmenopausal hormone replacement therapy: a longitudinal study. Radiology. 1990;174:487-490.
15. Lundstrom E, Wilczek B, von Palffy Z, et al. Mammographic breast density during hormone replacement therapy: differences according to treatment. Am J Obstet Gynecol. 1999;181:348-352.
16. Greendale GA, Reboussin BA, Sie A, et al. Effects of estrogen and estrogen-progestin replacement regimens on mammographic breast parenchymal density. Ann Intern Med. 1999;130:262-269.
17. Laya MB, Gallagher JC, Schreiman JS, et al. Effect of postmenopausal hormone replacement therapy on mammographic density and parenchymal pattern. Radiology. 1995;196:433-437.
18. Kaufman Z, Garstin WI, Hayes R, et al. The mammographic parenchymal patterns of women on hormonal replacement therapy. Clin Radiol. 1991;43:389-392.
19. Myles JP, Salmininen T, Duffy SW, et al. Prospective estimation of rates of change in mammographic parenchymal patterns: influence of age and of hormone replacement therapy. Breast. 2004;13:56-60.
20. Litherland JC, Evans AJ, Wilson AR. The effect of hormone replacement therapy on recall rate in the National Health Service Breast Screening Programme. Clin Radiol. 1997;52:276-279.
21. Banks E, Reeves G, Beral V, et al. Impact of use of hormone replacement therapy on false positive recall in the NHS breast screening programme: results from the Million Women Study. BMJ. 2004;328:1291-1292.
22. Harvey JA. Use and cost of breast imaging for postmenopausal women undergoing hormone replacement therapy. Am J Roentgenol. 1999;172:1615-1619.
23. Olsson P, Armelius K, Nordahl G, et al. Women with false positive screening mammograms: how do they cope? J Med Screen. 1999;6:89-93.
24. Barton MB, Morley DS, Moore S, et al. Decreasing women's anxieties after abnormal mammograms: a controlled trial. J Natl Cancer Inst. 2004;96:529-538.
25. Elmore JG, Nakano CY, Koepsell TD, et al. International variation in screening mammography interpretations in community-based programs. J Natl Cancer Inst. 2003;95:1384-1393.
26. Saunders KW, Davis RL, Stergachis A. Group Health Cooperative of Puget Sound. In: Strom B, Ed. Pharmacoepidemiology. 3rd ed. Chichester: John Wiley & Sons; 2000:247-262.
27. Taplin SH, Mandelson MT, Anderman C, et al. Mammography diffusion and trends in late-stage breast cancer: evaluating outcomes in a population. Cancer Epidmiol Biomarkers Prev. 1997;6:625-631.
28. Taplin SH, Ichikawa L, Buist DS, et al. Evaluating organized breast cancer screening implementation: the prevention of late-stage disease? Cancer Epidemiol Biomarkers Prev. 2004;13:225-234.
29. Liberman L, Menell JH. Breast imaging reporting and data system (BI-RADS). Radiol Clin North Am. 2002;40:409-430.
30. McCullagh P, Nelder JA. Generalized Linear Models (The Monographs on Statistics and Applied Probability, Vol 37). Cambridge, UK: University Press; 1989.
31. Fishman PA, Goodman MJ, Hornbrook MC, et al. Risk adjustment using automated ambulatory pharmacy data: The RxRisk Model. Med Care. 2003;41:84-99.
32. Blough DK, Madden CW, Hornbrook MC. Modeling risk using generalized linear models. J Health Econ. 1999;18:153-171.
33. Gilmer TP, O'Connor PJ, Manning WG, et al. The cost to health plans of poor glycemic control. Diabetes Care. 1997;20:1847-1853.
34. Fishman PA, Khan ZM, Thompson EE, et al. Health care costs among smokers, former smokers, and never smokers in an HMO. Health Serv Res. 2003;38:733-749.
35. Huber PJ. Robust Statistics. New York: Wiley; 1981.
36. Carney PA, Miglioretti DL, Yankaskas BC, et al. Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med. 2003;138:168-175.
37. El-Bastawissi AY, White E, Mandelson MT, et al. Reproductive and hormonal factors associated with mammographic breast density by age (United States). Cancer Causes Control. 2000;11:955-963.
38. Evans A. Hormone replacement therapy and mammographic screening. Clin Radiol. 2002;57:563-564.
39. Smith-Bindman R, Chu PW, Miglioretti DL, et al. Comparison of screening mammography in the United States and the United Kingdom. JAMA. 2003;290:2129-2137.
40. Buist DS, LaCroix AZ, Newton KM, et al. Are long-term hormone replacement therapy users different from short-term and never users? Am J Epidemiol. 1999;149:275-281.
41. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280:605-613.
42. Manson JE, Hsia J, Johnson KC, et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003;349:523-534.
43. Nelson HD. Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review. JAMA. 2004;291:1610-1620.